Karine Tawagi/X
Mar 30, 2025, 13:06
Karine Tawagi: Pluvicto FDA Approval for Use Pre-Chemotherapy in Prostate Cancer Based on PSMAfore Trial
Karine Tawagi, Assistant Professor of Clinical Medicine and Fellowship Program Director at the University of Illinois Chicago, shared a post on X:
“Pluvicto FDA approval pre-chemo based on PSMAfore in prostate cancer.
Lu-PSMA-617 versus ARPI switch in taxane-naïve mCRPC patients:
- Delayed worsening in pain + HRQoL + less AEs
- rPFS met
- no OS difference but results are likely confounded by rate of crossover.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 12:16
Apr 1, 2025, 12:13
Apr 1, 2025, 12:07
Apr 1, 2025, 11:53
Apr 1, 2025, 11:51
Apr 1, 2025, 11:42